parecoxib has been researched along with tetracaine in 1 studies
| Studies (parecoxib) | Trials (parecoxib) | Recent Studies (post-2010) (parecoxib) | Studies (tetracaine) | Trials (tetracaine) | Recent Studies (post-2010) (tetracaine) |
|---|---|---|---|---|---|
| 436 | 186 | 229 | 2,688 | 349 | 274 |
| Protein | Taxonomy | parecoxib (IC50) | tetracaine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 3.268 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 0.317 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 3.415 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 3.268 | |
| Sodium channel protein type 7 subunit alpha | Homo sapiens (human) | 0.056 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 0.5075 | |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | 1.4693 | |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | 0.795 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.673 | |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | 0.74 | |
| Sodium channel protein type 8 subunit alpha | Homo sapiens (human) | 0.52 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Song, ZS; Sun, JY; Xiao, XY; Zhang, XP | 1 |
1 trial(s) available for parecoxib and tetracaine
| Article | Year |
|---|---|
Efficacy and Safety of COX-2 Inhibitor Parecoxib for Rigid Cystoscopy-related Pain Management in Male Patients: A Prospective, Randomized and Controlled Study.
Topics: Ambulatory Care Facilities; Cyclooxygenase 2 Inhibitors; Cystoscopy; Double-Blind Method; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Pain; Pain Management; Pain Measurement; Prospective Studies; Tetracaine; Treatment Outcome | 2019 |